Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1366210 | Bioorganic & Medicinal Chemistry Letters | 2007 | 6 Pages |
Abstract
Discovery of the pyrazole-naphthyl urea class of p38 MAP kinase inhibitors typified by the clinical candidate BIRB 796 has encouraged further exploration of this particular scaffold. Modification to the part of the inhibitor that occupies the adenine/ATP binding site has resulted in a new way to obtain potent inhibitors that possess favorable in vitro and in vivo properties.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Neil Moss, Steffen Breitfelder, Raj Betageri, Pier F. Cirillo, Tazmeen Fadra, Eugene R. Hickey, Thomas Kirrane, Rachel R. Kroe, Jeffrey Madwed, Richard M. Nelson, Christopher A. Pargellis, Kevin C. Qian, John Regan, Alan Swinamer, Carol Torcellini,